Tag: CABOMETYX

US FDA approves Opdivo, Cabometyx combo for advanced renal cell carcinoma

pharmanewsdaily- January 26, 2021

The US Food and Drug Administration (FDA) has approved the combination of Bristol Myers Squibb’ Opdivo (nivolumab) and Exelixis’ Cabometyx (cabozantinib) as a first line ... Read More

COSMIC-311 clinical trial : Exelixis enrolls patients to study cabozantinib in phase 3 thyroid cancer trial

pharmanewsdaily- February 26, 2020

COSMIC-311 clinical trial : US biotech company Exelixis has enrolled the first 100 patients in a phase 3 trial called COSMIC-311 for evaluating cabozantinib (CABOMETYX) ... Read More